Cancers 2011, 3(3), 3055-3072; doi:10.3390/cancers3033055
Review

Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives

* email and email
Received: 7 June 2011; in revised form: 22 July 2011 / Accepted: 26 July 2011 / Published: 29 July 2011
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Intravesical instillation of bacillus Calmette Guérin (BCG) for the treatment of urothelial carcinoma (UC) of the bladder is based on the BCG-induced immune response, which eradicates and prevents bladder cancer. The results of recent studies have suggested that not only major histocompatibility complex (MHC)-nonrestricted immune cells such as natural killer cells, macrophages, neutrophils, etc., but also MHC-restricted CD8+ T cells play an important role and are one of the main effectors in this therapy. Better understanding of the mechanism of BCG immunotherapy supports the idea that active immunotherapy through its augmented T cell response can have great potential for the treatment of advanced UC. In this review, progress in immunotherapy for UC is discussed based on data from basic, translational and clinical studies. We also review the escape mechanism of cancer cells from the immune system, and down-regulation of MHC class I molecules.
Keywords: immunotherapy; urothelial cancer; cancer vaccine
PDF Full-text Download PDF Full-Text [527 KB, uploaded 29 July 2011 13:54 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Kitamura, H.; Tsukamoto, T. Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives. Cancers 2011, 3, 3055-3072.

AMA Style

Kitamura H, Tsukamoto T. Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives. Cancers. 2011; 3(3):3055-3072.

Chicago/Turabian Style

Kitamura, Hiroshi; Tsukamoto, Taiji. 2011. "Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives." Cancers 3, no. 3: 3055-3072.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert